For the parents of the 44 children diagnosed with retinoblastoma in the UK each year, treatment options have long meant an agonising trade-off: saving their child's life, but risking their sight.
Current treatments for this rare eye cancer — which overwhelmingly strikes children under five — include chemotherapy injections directly into the eye, laser therapy, radiotherapy, and in the most serious cases, surgical removal of the eye altogether. All are invasive, most require general anaesthetic, and many carry the risk of permanent vision loss.
Now, a team of researchers in China has developed something remarkably simple that could change all of that: eye drops.
Published in the journal Science Advances, the study by Yu Zhang and colleagues at Shenyang Pharmaceutical University describes a painless eye drop formulation that, in mice, shrank retinoblastoma tumours to just 2.35% of their original mass after 30 days of treatment — a reduction of nearly 98%.
The secret ingredient? Tiny particles called exosomes, derived from pig semen.
Why pig semen?
It sounds improbable, but the science is elegant. Exosomes are microscopic fat-coated bubbles that cells naturally release to transport proteins and other materials across biological barriers. Semen-derived exosomes have evolved specifically to help sperm penetrate the protective layers of the female reproductive tract — and it turns out that the mechanics of crossing that barrier are remarkably similar to penetrating the protective layers of the eye.
"Given that the majority of affected patients are young children, eye-preserving and toxicity-minimising therapies are critically important for their lifelong well-being," said study co-author Yu Zhang.
The team loaded the pig-derived exosomes with a targeted nanozyme system — a cocktail of carbon dots, manganese dioxide and glucose oxidase — designed to trigger intense oxidative stress in tumour cells, effectively causing them to self-destruct. Crucially, they also attached folic acid molecules to the exosomes, which act as a guidance system: retinoblastoma cells have far higher levels of folic acid receptors than healthy cells, so the drops home in on the cancer while leaving surrounding tissue unharmed.
A dual-pathway attack
The researchers found that their exosome-based eye drops could enter the eye via two routes — through the cornea at the front, and through the conjunctiva at the side — providing what they described as an "omnidirectional attack" against the tumour.
In mice, the results were striking. Animals treated with the drops not only showed dramatic tumour shrinkage but maintained near-normal eye clarity, while untreated mice developed severe clouding and abnormal blood vessel growth.
Owen Davies, an expert in extracellular vesicles at Loughborough University, told Live Science the work provided "interesting insights into the application of this technique."
What this means for families
Retinoblastoma affects roughly one in every 18,000 children, with most diagnosed before their second birthday. In the UK, all cases are referred to just two specialist centres — the Royal London Hospital and Birmingham Children's Hospital — meaning families in Scotland and elsewhere face long journeys south at an already devastating time.
While the 99% survival rate for retinoblastoma in the UK is reassuring, the toll of treatment is significant. Many children lose vision in one or both eyes. Some lose the eye itself. A painless eye drop that could target the tumour precisely, without needles, surgery or general anaesthetic, would be transformative.
The researchers acknowledge that significant hurdles remain before human trials can begin, including challenges around large-scale production, batch consistency, and ensuring the drops are free from contamination. But the principle — using the body's own biological delivery systems to ferry treatment exactly where it's needed — represents a genuine shift in how we might treat cancers in the most delicate parts of the body.
The team also believes the technology could eventually be applied to other eye conditions, including age-related macular degeneration and diabetic retinopathy.
For now, the work remains in the laboratory. But for the families of children facing retinoblastoma, even mouse-stage results this promising are a reason to feel hopeful about what comes next.
